209 related articles for article (PubMed ID: 30899264)
21. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
22. Fc-Gamma Receptor Polymorphisms Predispose Patients to Infectious Complications After Liver Transplantation.
Shimizu S; Tanaka Y; Tazawa H; Verma S; Onoe T; Ishiyama K; Ohira M; Ide K; Ohdan H
Am J Transplant; 2016 Feb; 16(2):625-33. PubMed ID: 26517570
[TBL] [Abstract][Full Text] [Related]
23. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
[TBL] [Abstract][Full Text] [Related]
24. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
25. Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation.
Arnold ML; Kainz A; Hidalgo LG; Eskandary F; Kozakowski N; Wahrmann M; Haslacher H; Oberbauer R; Heilos A; Spriewald BM; Halloran PF; Böhmig GA
Am J Transplant; 2018 Sep; 18(9):2261-2273. PubMed ID: 29478298
[TBL] [Abstract][Full Text] [Related]
26. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
27. Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.
Zhang X; Olsen HS; Chen S; So E; Zhou H; Burch E; Mérigeon EY; Block DS; Strome SE
J Immunol; 2016 Feb; 196(3):1165-76. PubMed ID: 26695368
[TBL] [Abstract][Full Text] [Related]
28. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
[TBL] [Abstract][Full Text] [Related]
29. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.
Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A
Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013
[TBL] [Abstract][Full Text] [Related]
30. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
Kjersem JB; Skovlund E; Ikdahl T; Guren T; Kersten C; Dalsgaard AM; Yilmaz MK; Fokstuen T; Tveit KM; Kure EH
BMC Cancer; 2014 May; 14():340. PubMed ID: 24884501
[TBL] [Abstract][Full Text] [Related]
31. FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.
Wang W; Somers EB; Ross EN; Kline JB; O'Shannessy DJ; Schweizer C; Weil S; Grasso L; Nicolaides NC
Cytogenet Genome Res; 2017; 152(4):169-179. PubMed ID: 29041009
[TBL] [Abstract][Full Text] [Related]
32. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
[TBL] [Abstract][Full Text] [Related]
33. FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy.
Tanaka Y; Suzuki Y; Tsuge T; Kanamaru Y; Horikoshi S; Monteiro RC; Tomino Y
Nephrol Dial Transplant; 2005 Nov; 20(11):2439-45. PubMed ID: 16221721
[TBL] [Abstract][Full Text] [Related]
34. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
35. Fc gamma RIIa, IIIa and IIIb polymorphisms in Turkish children susceptible to recurrent infectious diseases.
Ozturk C; Aksu G; Berdeli A; Kutukculer N
Clin Exp Med; 2006 Mar; 6(1):27-32. PubMed ID: 16550341
[TBL] [Abstract][Full Text] [Related]
36. Optimization of a bovine cytokine multiplex assay using a new bovine and cross-reactive equine monoclonal antibodies.
Sipka A; Babasyan S; Asbie S; Freer H; Wagner B
Vet Immunol Immunopathol; 2024 Jul; 273():110789. PubMed ID: 38820946
[TBL] [Abstract][Full Text] [Related]
37. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
[TBL] [Abstract][Full Text] [Related]
38. FC gamma receptor polymorphisms in patients with immune thrombocytopenia.
Pavkovic M; Petlichkovski A; Karanfilski O; Cevreska L; Stojanovic A
Hematology; 2018 Apr; 23(3):163-168. PubMed ID: 28942727
[TBL] [Abstract][Full Text] [Related]
39. The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A.
Eckhardt CL; Astermark J; Nagelkerke SQ; Geissler J; Tanck MW; Peters M; Fijnvandraat K; Kuijpers TW
J Thromb Haemost; 2014 Aug; 12(8):1294-301. PubMed ID: 24916518
[TBL] [Abstract][Full Text] [Related]
40. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
